Description

Release form, composition and packaging

?

Drops for oral administration in the form of a clear, slightly viscous, colorless or weakly colored liquid.

1 ml (15 drops)

sodium picosulfate 7.5 mg

sodium methyl parahydroxybenzoate (in terms of anhydrous substance) - 2.06 mg, sorbitol - 375 mg, hydrochloric acid solution 1M - 0.01 ml, purified water - up to 1 ml.

15 ml - dark glass dropper bottle (1) - cardboard packs.

30 ml - dark glass dropper bottle (1) - cardboard packs.

pharmachologic effect

Laxative.

Under the action of intestinal microorganisms, it is hydrolyzed to form an active form, which irritates the receptors of the intestinal mucosa and increases its peristalsis.

Pharmacokinetics

After oral administration, it is not absorbed from the gastrointestinal tract and does not undergo hepatic-intestinal circulation.

Indications for use

Constipation due to hypotension and sluggish peristalsis of the colon.

Stool regulation for hemorrhoids, proctitis, anal fissures.

Preparation for surgical operations, instrumental and X-ray examinations.

Contraindications for use

Intestinal obstruction, strangulated hernia, acute inflammatory diseases of the abdominal organs, peritonitis, abdominal pain of unknown origin, bleeding from the gastrointestinal tract, uterine bleeding, cystitis, spastic constipation, children under 4 years of age, I trimester of pregnancy, severe dehydration, hypersensitivity to sodium picosulfate.

Dosage regimen

Individual, depending on the patient's age and response to treatment.

It is taken orally before bedtime.

Side effect

Possibly: diarrhea, which can lead to excessive loss of fluid and electrolytes, weakness, seizures, arterial hypotension, and abdominal pain.

Drug interactions

With simultaneous use with broad-spectrum antibiotics, it is possible to reduce the laxative effect of sodium picosulfate.

With simultaneous use with diuretics, with GCS, an increase in the risk of electrolyte disturbances is possible.

The electrolyte imbalance that occurs while taking sodium picosulfate in high doses can lead to a deterioration in the tolerance of cardiac glycosides when used simultaneously.

Application during pregnancy and lactation

Contraindicated in the first trimester of pregnancy.

It should be used in the II and III trimester of pregnancy only if the intended benefit to the mother outweighs the possible risk to the fetus.

If necessary, use during lactation should stop breastfeeding.

Special instructions It has no taste, so children can add to food.

Do not use daily without medical supervision for more than 10 days.

Name ENG

SLABILEN

Clinical and pharmacological group

Laxative drug that stimulates intestinal motility

ATX code

Sodium picosulfate

Dosage

7.5mg / ml x 15ml

Structure

1 ml of oral drops contains: Active ingredient: sodium picosulfate 7.5 mg

Excipients: sodium methylparaben, sorbitol, 1 M hydrochloric acid solution, purified water.

Indications

Constipation due to hypotension and sluggish peristalsis of the colon.

Stool regulation for hemorrhoids, proctitis, anal fissures.

Preparation for surgical operations, instrumental and X-ray examinations

INN / Active ingredient

sodium picosulfate

Contraindications

Intestinal obstruction, strangulated hernia, acute inflammatory diseases of the abdominal organs, peritonitis, abdominal pain of unknown origin, bleeding from the gastrointestinal tract, uterine bleeding, cystitis, spastic constipation, children under 4 years of age, I trimester of pregnancy, severe dehydration, hypersensitivity to sodium picosulfate

Storage conditions and periods

At a temperature of 8-25 degrees. (Do not freeze).

Expiration date: 4 years

Specifications